Evidence map›Paper›PMID 37467351›Full record

ArticleSchizophrenia bulletin2023

Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study.

Elisa Rodríguez-Toscano, Clara Alloza, David Fraguas, Manuel Durán-Cutilla, Laura Roldán, Teresa Sánchez-Gutiérrez, Gonzalo López-Montoya, Mara Parellada, Carmen Moreno, Charlotte Gayer-Anderson and 32 more

Open access · greenAbstract read
In one paragraph

Article in Schizophrenia bulletin, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. SIPD or psychotic disorder with stimulant use.Schizophrenia research. Cognition · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

42 authors at 20 institutions in 7 countries.

Elisa Rodríguez-ToscanoInstitute of Psychiatry and Mental Health, Hospital Clínico San Carlos, IdISSC, School of Medicine, Universidad Complutense, Madrid, Spain.ORCID 0000-0001-8305-0123
Clara AllozaDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain.
David FraguasInstitute of Psychiatry and Mental Health, Hospital Clínico San Carlos, IdISSC, School of Medicine, Universidad Complutense, Madrid, Spain.
Manuel Durán-CutillaDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain.
Laura RoldánFaculty of Psychology, Universidad Complutense, Madrid, Spain.
Teresa Sánchez-GutiérrezFaculty of Health Science, Universidad Internacional de la Rioja (UNIR), Madrid, Spain.ORCID 0000-0003-3124-4975
Gonzalo López-MontoyaDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain.
Mara ParelladaDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain.
Carmen MorenoDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain.
Charlotte Gayer-AndersonDepartment of Health Services and Population Research, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.ORCID 0000-0003-1636-889X
Hannah E JongsmaPsyLife Group, Division of Psychiatry, University College London, London, UK.
Marta Di FortiSocial, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Diego QuattroneSocial, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Eva VelthorstDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA.
Lieuwe de HaanEarly Psychosis Section, Department of Psychiatry, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Jean-Paul SeltenInstitute for Mental Health, GGZ Rivierduinen, Leiden, The Netherlands.
Andrei SzökeInstitut National de la Santé et de la Recherche Médicale, U955, Equipe 15 Neuro-Psychiatrie Translationnelle, Créteil, France.
Pierre-Michel LlorcaEA 7280 Npsydo, Université Clermont Auvergne, Clermont-Ferrand, France.
Andrea TortelliPôle Psychiatrie Précarité, Groupe Hospitalier Universitaire Paris Psychiatrie and Neurosciences, 75014 Paris, France.
Julio BobesDepartment of Medicine, Psychiatry Area, School of Medicine, Universidad de Oviedo, ISPA, INEUROPA, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Oviedo, Spain.
Miguel BernardoBarcelona Clinic Schizophrenia Unit, Hospital Clínic of Barcelona; Departament de Medicina, Institut de Neurociències (UBNeuro), Universitat de Barcelona (UB); Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS); CIBERSAM, ISCIII, Barcelona, Spain.ORCID 0000-0001-8748-6717
Julio SanjuánDepartment of Psychiatry, School of Medicine, Universidad de Valencia, Centro de Investigación Biomédica en Red de Salud Mental, Valencia, Spain.
José Luis SantosDepartment of Psychiatry, Hospital "Virgen de la Luz", Cuenca, Spain.
Manuel ArrojoDepartment of Psychiatry, Psychiatric Genetic Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain.
Ilaria TarriconeDepartment of Biomedical and NeuroMotor Sciences, Psychiatry Unit, Alma Mater Studiorium Università di Bologna, Bologna, Italy.
Domenico BerardiAlma Mater Studiorium Università di Bologna, Bologna, Italy.
Mirella RuggeriSection of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.
Antonio LasalviaSection of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.ORCID 0000-0001-9963-6081
Laura FerraroDepartment of Biomedicine, Neuroscience and advanced Diagnostic (BiND), Psychiatry section, University of Palermo, Palermo, Italy.ORCID 0000-0002-1205-2356
Caterina La CasciaDepartment of Biomedicine, Neuroscience and advanced Diagnostic (BiND), Psychiatry section, University of Palermo, Palermo, Italy.
Daniele La BarberaDepartment of Biomedicine, Neuroscience and advanced Diagnostic (BiND), Psychiatry section, University of Palermo, Palermo, Italy.
Paulo Rossi MenezesDepartment of Preventive Medicine, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Cristina Marta Del-BenDivision of Psychiatry, Department of Neuroscience and Behaviour, Ribeirão Preto Medical School, Universidade de São Paulo, São Paulo, Brazil.
EU-GEI WP2 Group
Bart P RuttenDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.
Jim van OsDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.
Peter B JonesDepartment of Psychiatry, University of Cambridge, Cambridge, UK.ORCID 0000-0002-0387-880X
Robin M MurrayDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
James B KirkbridePsyLife Group, Division of Psychiatry, University College London, London, UK.ORCID 0000-0003-3401-0824
Craig MorganDepartment of Health Services and Population Research, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Covadonga M Díaz-CanejaDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain.ORCID 0000-0001-8538-3175
Celso ArangoDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain.
Hospital Clínico San Carlos · ESHospital General Universitario Gregorio Marañón · ESKing's College London · GBUniversity of Verona · ITUniversidade de São Paulo · BRAmsterdam University Medical Centers · NLMaastricht University Medical Centre · NLNational Health Service · GBUniversidad Complutense de Madrid · ESUniversité Clermont Auvergne · FRUniversity of Bologna · ITUniversity of Palermo · ITCentro de Investigación Biomédica en Red de Salud Mental · ESComplejo Hospitalario Universitario de Santiago · ESFHU Neurovasc · FRHospital Virgen de la Luz · ESInserm · FRUniversidad de Oviedo · ESUniversidad Internacional De La Rioja · ESUniversitat de València · ES

Funding

ProNET: Psychosis-Risk Outcomes NetworkU01MH124639 · NIMH · YALE UNIVERSITY · PI CARRIE E BEARDEN, JOHN M KANE · 2020 to 2026
$81.2M
Randomized controlled trial of enhanced coordinated specialty care (CSC 2.0)P50MH115846 · NIMH · MCLEAN HOSPITAL · PI MIGUEL HERNAN · 2019 to 2026
$16.9M
NIMH NIH HHS P50 MH115846NIMH NIH HHS U01 MH124639
6 · The paper itself

Abstract

backgroundUse of illegal stimulants is associated with an increased risk of psychotic disorder. However, the impact of stimulant use on odds of first-episode psychosis (FEP) remains unclear. Here, we aimed to describe the patterns of stimulant use and examine their impact on odds of FEP.

methodsWe included patients with FEP aged 18-64 years who attended psychiatric services at 17 sites across 5 European countries and Brazil, and recruited controls representative of each local population (FEP = 1130; controls = 1497). Patterns of stimulant use were described. We computed fully adjusted logistic regression models (controlling for age, sex, ethnicity, cannabis use, and education level) to estimate their association with odds of FEP. Assuming causality, we calculated the population-attributable fractions for stimulant use associated with the odds for FEP.

findingsPrevalence of lifetime and recent stimulant use in the FEP sample were 14.50% and 7.88% and in controls 10.80% and 3.8%, respectively. Recent and lifetime stimulant use was associated with increased odds of FEP compared with abstainers [fully adjusted odds ratio 1.74,95% confidence interval (CI) 1.20-2.54, P = .004 and 1.62, 95% CI 1.25-2.09, P < .001, respectively]. According to PAFs, a substantial number of FEP cases (3.35% [95% CI 1.31-4.78] for recent use and 7.61% [95% CI 3.68-10.54] for lifetime use) could have been prevented if stimulants were no longer available and the odds of FEP and PAFs for lifetime and recent stimulant use varied across countries.

interpretationIllegal stimulant use has a significant and clinically relevant influence on FEP incidence, with varying impacts across countries.

Indexed as

CannabisCentral Nervous System StimulantsPsychotic DisordersEthnicityEuropeHumansIncidenceCentral Nervous System Stimulantsamphetaminesfirst episode psychosismethamphetaminepopulation attributable fractionsstimulant use

Identifiers

PMID37467351
PMCPMC10483438
OpenAlexW4384704839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.